J&J Showcases Neuropsychiatry Data at Psych Congress 2026, but Core Risks Remain

What happened

Johnson & Johnson presented 24 abstracts at the 2026 Psych Congress, including first pivotal Phase 3 data for CAPLYTA in bipolar mania and new SPRAVATO analyses. The data underscores the company's ambition to expand its neuropsychiatry franchise, an area bolstered by the $14.5B Intra-Cellular acquisition. However, the presentations are academic in nature and do not alter the near-term operating or legal challenges facing J&J, namely talc litigation exposure and STELARA biosimilar erosion. Management's growth narrative already includes SPRAVATO and CARVYKTI among offsetting drivers, but the report's WAIT rating reflects a need for confirmation of immunology stabilization and bounded talc risk. This news is unlikely to shift the stock's fundamental risk-reward until commercial uptake or regulatory milestones are demonstrated.

Implication

The neuropsychiatry data supports the longer-term growth thesis by validating CAPLYTA's expansion potential beyond schizophrenia, but it is early-stage and not yet commercial. J&J's existing growth drivers like DARZALEX and TREMFYA are more material to near-term revenue, and the CVS formulary switch on July 1, 2026, could accelerate STELARA decline faster than currently modeled. The talc litigation overhang remains unbounded, with ~75,000 plaintiffs and a reserve of only $3.4B, and any adverse evidentiary rulings could sharply increase expected liabilities. Thus, the WAIT rating is unchanged: better entries may appear if immunology deteriorates post-CVS or talc risk escalates, while confirmation of stabilization would support upgrading. Investors should monitor upcoming quarterly results for signs of STELARA volume loss and any changes in talc disclosure, rather than reading too much into conference presentations.

Thesis delta

This news does not alter the core WAIT thesis. It reinforces the pipeline strength but does not address the near-term headwinds of STELARA erosion and talc litigation. No change in rating or price targets is warranted at this time.